Losartan Potassium ( DrugBank: Losartan, Potassium )
5 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 36 | Epidermolysis bullosa | 2 |
| 98 | Eosinophilic gastrointestinal disease | 2 |
| 167 | Marfan syndrome | 4 |
| 179 | Williams syndrome | 1 |
| 215 | Tetralogy of Fallot | 1 |
36. Epidermolysis bullosa
Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-003670-32-AT (EUCTR) | 05/10/2017 | 07/08/2017 | Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosa | A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Losartan HEXAL INN or Proposed INN: losartan potassium Other descriptive name: LOSARTAN POTASSIUM | Medical Center - University of Freiburg | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Austria;Germany | ||
| 2 | EUCTR2015-003670-32-DE (EUCTR) | 07/04/2016 | Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosa | A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Losartan HEXAL INN or Proposed INN: losartan potassium Other descriptive name: LOSARTAN POTASSIUM | Medical Center - University of Freiburg | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Austria;Germany |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03029091 (ClinicalTrials.gov) | May 23, 2017 | 20/1/2017 | An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) | A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder | Eosinophilic Esophagitis | Drug: Losartan Potassium | Children's Hospital Medical Center, Cincinnati | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS) | Completed | 5 Years | 25 Years | All | 15 | Phase 2 | United States |
| 2 | NCT01808196 (ClinicalTrials.gov) | October 10, 2013 | 30/1/2013 | Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD | A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. | Eosinophilic Esophagitis;Connective Tissue Disorders | Drug: Losartan Potassium | Children's Hospital Medical Center, Cincinnati | NULL | Completed | 5 Years | 21 Years | All | 6 | Phase 2 | United States |
167. Marfan syndrome
Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-005862-10-BE (EUCTR) | 29/05/2009 | 07/01/2009 | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Marfan syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: Cozaar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium | University Hospital Ghent | NULL | Not Recruiting | Female: yes Male: yes | Belgium | ||||
| 2 | EUCTR2007-001125-97-ES (EUCTR) | 20/05/2008 | 03/12/2007 | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: cozaar 50 INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: blokium 50 INN or Proposed INN: ATENOLOL Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: BLOKIUM 50 mg comprimidos INN or Proposed INN: ATENOLOL | alberto forteza | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
| 3 | NCT00429364 (ClinicalTrials.gov) | January 2007 | 29/1/2007 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network | Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) | Marfan Syndrome | Drug: Losartan Potassium;Drug: Atenolol | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan Foundation | Completed | 6 Months | 25 Years | All | 608 | Phase 3 | United States;Belgium;Canada |
| 4 | EUCTR2006-003991-37-BE (EUCTR) | 13/12/2006 | 06/12/2006 | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Marfan syndrome MedDRA version: 8.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol | University Hospital Gent | NULL | Not Recruiting | Female: yes Male: yes | 600 | Belgium |
179. Williams syndrome
Clinical trials : 5 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 8 - Drug target pathways : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-006059-37-ES (EUCTR) | 27/05/2009 | 19/08/2008 | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1. MedDRA version: 9.1;Level: LLT;Classification code 10049644;Term: Williams syndrome | Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula INN or Proposed INN: LOSARTAN POTASICO Other descriptive name: LOSARTAN POTASSIUM | Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Spain |
215. Tetralogy of Fallot
Clinical trials : 18 / Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-002091-41-NL (EUCTR) | 09/10/2014 | 05/11/2013 | Research into the effect of the drug losartan in adult patients with a reduced function of the right cardiac chamber and a cardiac birth defect | Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system - Redefine trial | To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Losartan Product Name: Losartan INN or Proposed INN: Losartan Potassium Other descriptive name: LOSARTAN POTASSIUM | Academisch medisch centrum | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |